Recorded device evidence

Cala kIQ (K242259): indications, design and recorded evidence

The acquired K242259 file contains product-specific indications and users, design and operating principle, performance evidence actually described, clinical evidence or its stated absence sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 5 selected decisions under primary code QBC. 5 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K242259 ↗ · this pageCala kIQ2024-07-31 → 2024-11-22114Traditional
K253587 ↗Cala kIQ Plus2025-11-17 → 2026-03-17120Traditional
K251517 ↗Encora X12025-05-16 → 2026-02-05265Traditional
K250096 ↗Felix NeuroAI System2025-01-14 → 2025-07-01168Traditional
K243848 ↗Cala kIQ2024-12-16 → 2025-01-1631Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 1 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K242259 · PDF page 4 ↗ Source 2

Cala           klQ     is     indicated  to        aid         in       the     temporary       relief    of hand       tremors      in     the       treated   hand       following
  stimulation        in          adults   with        essential   tremor.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K242259 · PDF page 6 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K242259 · PDF page 10 ↗ Source 4

User Workflow                    1.   Calibration                                          1.   Calibration                                                        Yes
                                    2.   Set stimulation intensity                            2.   Set stimulation intensity                            Subject Device is identical
                                    3.   Therapy available on demand                          3.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Clinical evidence or its stated absence

K242259 · PDF page 14 ↗ Source 5

There was no clinical testing conducted in support of Cala kIQ Gen 2 premarket application.

Compare with your product: Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK242259 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryCala kIQ [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantCala Health, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeQBC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2024-11-22 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2024-07-31 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

  4. Clinical evidence or its stated absence — what differs in our product?

    Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

    Useful evidence: Your proposed claims and supporting evidence, plus a reviewed rationale for clinical-evidence needs.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[77256] · record df3279e32e65014f8333f1b4a3ea31d09d28afd541018ab92757d782e039af5a
  • [6] Complete results array / fda-decision-context:K242259 · record whole dataset partition

FDA 510(k) summary — K242259 ↗

Sat, 23 Nov 2024 16:47:02 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot ea3044f3f95ba2db517b87226497624ffdea6ebfaf83b08213d21c72f8ba1060

  • [2] PDF page 4 · record dbbccb0aa55ed5a95167158ae480434f280cb8e150d104280b52f824e226e3da
  • [3] PDF page 6 · record 890cf1bf5a1ce0234cce4aca0a26b45b74747900072cd802389daeec535eade3
  • [4] PDF page 10 · record 4f31f9102b3f38165a0ad96981c36f47395634888da088a3997354f9f39b8a76
  • [5] PDF page 14 · record 09c79bf7c850efa797a1bf25ac6f59b698ee7c800728b76a674bf7b6cd8e534b

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services